KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy (cisplatin plus 5-fluorouracil [5-FU]), met its primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with locally advanced or metastatic esophageal cancer.
Expectant parents have so many decisions to make before and after their childs birth. Until recently, decisions related to the Umbilical cord blood banking werent one of those
- PDUFA action date of February 15, 2021 assigned by U.S.
Memphis Meats' lab-produced meatballs There is a frustrating, 'jam tomorrow' aspect to all the talk around cell-based meat. Perhaps it is the tantalising prospect of what might be achieved by the men and women in labs and what it might mean for the future of food that makes us keep asking the question of when we will see something more than a prototype of meat created without harming animals.
As the on-going COVID-19 pandemic continues we are facing a huge healthcare crisis.
TOKYO, Japan: The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome
Every successful medicinal activity requires mass production of quality stem cells. This is what avails regenerative medicine to the public the need occasioned the founding of Cellect Biotechnology Ltd ADR (NASDAQ:APOP). In 2011
A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeuticrelated cytokine release syndrome Wiley
A complete research offering of comprehensive analysis of the market share, size, recent developments, and trends can be availed in this latest report by Big Market Research. As per the report, theGlobal Autologous Stem Cell Based Therapies Industry Marketis anticipated to witness significant growth during the forecast period from 2020to 2025. The report provides brief summary and detailed insights of the market by collecting data from the industry experts and several prevalent in the market.
Jae Park, MD, discussesthebenefits of off-the-shelf CAR T-cell therapy inacute lymphoblasticleukemia. Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discussesthebenefits of off-the-shelf CAR T-cell therapy inacute lymphoblasticleukemia (ALL). Patients with low lymphocyte counts afterchemotherapy or allogeneic stem cell transplantationcould benefit from off-the-shelf CAR T-cell products ascollectingT cellscan be challenging, says Park
Recent Comments